Pozen Inc. (POZN), a pharmaceutical company, said Monday that the U.S. Food and Drug Administration or FDA has accepted the New Drug Application or NDA for Vimovo or enteric-coated naproxen / immediate release esomeprazole magnesium, formerly known as PN 400.
Vimovo is a fixed-dose combination of enteric-coated naproxen, a pain-relieving non-steroidal anti-inflammatory drug and immediate release esomeprazole, a proton pump inhibitor. It is under investigation for the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis in patients who are at risk of developing gastric ulcers associated with non-steroidal anti-inflammatory drug.
Nearly 27 million US residents and 140 million people worldwide suffer from osteoarthritis, which is commonly treated with non-steroidal anti-inflammatory drugs. According to the company, half of osteoarthritis patients on chronic non-steroidal anti-inflammatory drugs therapy are at the risk of developing gastric ulcers associated with it.
Only a quarter of osteoarthritis patients on non-steroidal anti-inflammatory drugs are prescribed the gastroprotective agent therapy they need, and up to 60% of patients will not adhere to the recommended proton pump inhibitor co-therapy after the third prescription of non-steroidal anti-inflammatory drug, which makes Vimovo a potentially important treatment option, Pozen said.
As per an agreement between Pozen and drug maker AstraZeneca (AZN), the FDA's notification of acceptance of the NDA filing for Vimovo prompts a $10 million milestone payment from AstraZeneca to Pozen.
POZN closed Friday's regular trade at $6.47, down from the previous close of $6.58, on 50,400 shares.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.